OpGen

US: OPGN

$9.6m market cap

$0.56 last close

OpGen is a diagnostic company focused on revolutionizing the identification and treatment of bacterial infections. The Acuitas AMR Gene Panel molecular test, in combination with the Acuitas Lighthouse bioinformatics product, detects multiple pathogens and predicts antibiotic resistance in less than three hours, a major improvement on the two to three days that current methods require.

Investment summary

OpGen is a diagnostic company focused on revolutionizing the identification and treatment of bacterial infections. The Acuitas AMR Gene Panel molecular test, in combination with the Acuitas Lighthouse bioinformatics product, allows for the detection of five pathogens as well as 47 resistance genes and mutations, while also predicting the resistance for 14 antibiotics in less than three hours, a major improvement over the two to three days current methods require. OpGen expects to initiate the 510(k) clearance processes for its products in Q219.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2017A 3.2 (15.3) (15.6) (981.24) N/A N/A
2018A 2.9 (13.2) (13.4) (167.56) N/A N/A
2019E 4.0 (13.4) (13.6) (79.71) N/A N/A
2020E 5.0 (15.3) (15.5) (89.95) N/A N/A
Last updated on 18/04/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net debt (US$m) 3.5
Forecast gearing ratio (%) 157
Price performance
%
1m
3m
12m
Actual (37.0) (65.9) (71.5)
Relative* (39.7) (69.2) (74.3)
52-week high/low US$2.8/US$0.5
*% relative to local index
Key management
Evan Jones CEO
Tim Dec CFO